A cleavable antibody specifically targeting mesothelin+ tumor cells and containing the chemoattractant CXCL16, which binds CXCR6, improved NK cell infiltration after adoptive transfer, which reduced tumor burden and prolonged survival in orthotopic or metastatic PDA murine models (98). Here, MSLN is linked to Patent ductus arteriosus.